Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHA:600572)

SHA:600572 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	6,287	6,426	6,652	5,945	6,531	5,863
Other Revenue	89.02	89.02	80.59	54.95	37.67	46.16
Revenue	6,376	6,515	6,733	6,000	6,568	5,909
Revenue Growth (YoY)	-0.79%	-3.23%	12.21%	-8.64%	11.15%	-12.70%
Cost of Revenue	3,078	3,101	2,835	2,470	2,626	2,088
Gross Profit	3,298	3,414	3,897	3,531	3,942	3,821
Selling, General & Admin	2,435	2,480	2,832	2,581	2,964	2,967
Research & Development	292.71	300.02	298.09	195.72	202.49	184.99
Other Operating Expenses	58.65	52.8	-38.49	62.99	64.65	75.31
Operating Expenses	2,786	2,834	3,093	2,840	3,268	3,239
Operating Income	511.77	579.93	804.32	690.41	674.18	581.56
Interest Expense	-14.93	-20.79	-36.4	-49.47	-73.22	-123.65
Interest & Investment Income	91.59	101.92	135.27	89.35	2,611	302.83
Currency Exchange Gain (Loss)	5.22	5.22	3.09	-1.11	0.06	-6.16
Other Non Operating Income (Expenses)	-0.89	-1.06	-21.98	-3.76	-9.31	-1.09
EBT Excluding Unusual Items	592.75	665.22	884.3	725.42	3,203	753.5
Impairment of Goodwill	-	-	-	-	-	-52.99
Gain (Loss) on Sale of Investments	46.51	30.27	-146.04	-238.23	-714.69	34.63
Gain (Loss) on Sale of Assets	15.89	20.55	35.68	36.02	42.22	-4.86
Asset Writedown	2.92	-5.46	-7.18	-1.84	-95.71	-48.15
Other Unusual Items	77.46	69.36	0.93	68.64	92.55	83.52
Pretax Income	735.53	779.94	767.69	590.01	2,527	765.65
Income Tax Expense	114.12	121.59	92.97	129.89	391.13	216.45
Earnings From Continuing Operations	621.41	658.35	674.72	460.12	2,136	549.2
Minority Interest in Earnings	-25.66	-35.94	-83.15	-102	-118.31	-95.9
Net Income	595.75	622.42	591.57	358.12	2,017	453.3
Net Income to Common	595.75	622.42	591.57	358.12	2,017	453.3
Net Income Growth	13.82%	5.21%	65.19%	-82.25%	345.06%	-
Shares Outstanding (Basic)	2,515	2,527	2,572	2,558	2,586	2,518
Shares Outstanding (Diluted)	2,628	2,531	2,572	2,558	2,586	2,518
Shares Change (YoY)	2.06%	-1.59%	0.55%	-1.10%	2.71%	-5.28%
EPS (Basic)	0.24	0.25	0.23	0.14	0.78	0.18
EPS (Diluted)	0.23	0.25	0.23	0.14	0.78	0.18
EPS Growth	13.47%	7.09%	64.29%	-82.05%	333.33%	-
Free Cash Flow	749.64	721.9	689.5	863.73	309.8	789.3
Free Cash Flow Per Share	0.28	0.28	0.27	0.34	0.12	0.31
Dividend Per Share	0.150	0.150	0.200	0.150	0.160	-
Dividend Growth	-25.00%	-25.00%	33.33%	-6.25%	-	-
Gross Margin	51.72%	52.41%	57.88%	58.84%	60.02%	64.66%
Operating Margin	8.03%	8.90%	11.95%	11.51%	10.26%	9.84%
Profit Margin	9.34%	9.55%	8.79%	5.97%	30.72%	7.67%
Free Cash Flow Margin	11.76%	11.08%	10.24%	14.39%	4.72%	13.36%
EBITDA	847.95	913.75	1,129	963.34	956.65	847.64
EBITDA Margin	13.30%	14.03%	16.76%	16.05%	14.56%	14.34%
D&A For EBITDA	336.19	333.82	324.35	272.93	282.47	266.07
EBIT	511.77	579.93	804.32	690.41	674.18	581.56
EBIT Margin	8.03%	8.90%	11.95%	11.51%	10.26%	9.84%
Effective Tax Rate	15.52%	15.59%	12.11%	22.02%	15.48%	28.27%
Revenue as Reported	6,376	6,515	6,733	6,000	6,568	5,909

Source: S&P Global Market Intelligence. Standard template. Financial Sources.